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Enterovirus D68 (EV-D68), a member of human enterovirus species D, was first isolated from children with respiratory infections in 19621. It was considered an obscure pathogen 
until more frequent clusters of infections were recognized during 
the last decade in Europe, North America and Japan2–4. In particu-
lar, an outbreak in the United States in 2014 accounted for 1,153 
cases and 14 deaths5,6. EV-D68 replicates primarily in the human 
respiratory tract causing bronchiolitis and pneumonia, and has 
been associated with fever, cough and wheezing. Importantly, it has 
also been associated with severe neurological complications such 
as paralysis, acute flaccid myelitis and cranial nerve dysfunction7,8. 
Although EV-D68 poses a substantial public health threat, the 
dearth of virology and immunology information on this emerging 
picornavirus hinders the design and development of effective vac-
cines and therapeutics. The crystal structures of the mature EV-D68 
virion and its complexes with a potential drug or sialic acid receptor 
have recently been reported9,10 and the major features of EV-D68 
are similar to those of other known picornaviruses, such as poliovi-
rus, human rhinovirus (HRV) and enterovirus A71 (EV71)11–14. The 
capsid of EV-D68 contains 60 copies of each of four proteins VP1 
to VP4, arranged with pseudo T = 3 symmetry9. The capsid accom-
modates deep surface depressions (‘canyons’) around each icosahe-
dral five-fold axis, which can be bound by the sialic acid receptor. 
Such binding can trigger a series of conformational changes of the 
capsid, such as collapse of the pocket and conformational changes 
at receptor-binding sites, leading to an earlier intermediate state that 
is different from the classical uncoating intermediates (so-called 
‘A-particles’) of other picornaviruses10,15–17. In addition to sialic acid, 
intercellular adhesion molecule 5 (ICAM-5) has been identified as a 
functional receptor for EV-D68, but the binding site and the in vivo 
role of ICAM-5 remain unclear10,18.
It is well known that picornaviruses generally undergo structural 
transitions of their capsids and four major particle forms can be 
observed during the life cycle: procapsid, mature virion, A-particle 
and empty particle11–13,15,17. Such particle variation is necessary for 
viral infection and is a structural form of immune flummox that 
represents an obstacle for vaccine development against EV-D6819,20. 
As powerful tools for investigating neutralizing mechanisms, neu-
tralizing antibodies against picornavirus EV71 and HRV have been 
shown to promote premature uncoating of virions and genome 
release21,22. However, more detailed neutralization mechanisms 
related to whether neutralizing antibodies can cross-react with 
viruses at different conformational states of the life cycle, or inter-
fere with dynamic transitions between states have not been exten-
sively studied.
Here we show two EV-D68-specific neutralizing antibodies, 
15C5 and 11G1, that exhibit different binding properties and neu-
tralizing mechanisms. Near-atomic-resolution cryogenic electron 
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Enterovirus D68 (EV-D68) undergoes structural transformation between mature, cell-entry intermediate (A-particle) and 
empty forms throughout its life cycle. Structural information for the various forms and antibody-bound capsids will facilitate 
the development of effective vaccines and therapeutics against EV-D68 infection, which causes childhood respiratory and para-
lytic diseases worldwide. Here, we report the structures of three EV-D68 capsid states representing the virus at major phases. 
We further describe two original monoclonal antibodies (15C5 and 11G1) with distinct structurally defined mechanisms for virus 
neutralization. 15C5 and 11G1 engage the capsid loci at icosahedral three-fold and five-fold axes, respectively. To block viral 
attachment, 15C5 binds three forms of capsids, and triggers mature virions to transform into A-particles, mimicking engage-
ment by the functional receptor ICAM-5, whereas 11G1 exclusively recognizes the A-particle. Our data provide a structural 
and molecular explanation for the transition of picornavirus capsid conformations and demonstrate distinct mechanisms for 
antibody-mediated neutralization.
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microscopy (cryoEM) structures of procapsid, mature virion, 
A-particle and three neutralizing antibody-bound viral complexes 
reveal that the neutralizing antibody 11G1 specifically binds the 
A-particle, but the neutralizing antibody 15C5 binds and triggers 
the transformation of mature virions into classical A-particles, thus 
mimicking host receptor interactions. These results provide atomic-
level details and insights into the process of virus entry and potential 
mechanisms of antibody neutralization, and inform a structure-
based rationale for the design of EV-D68 vaccines and therapeutics.
Results
ICAM-5-induced EV-D68 A-particle shares similar structure 
to procapsid. A clinical EV-D68 strain (GenBank accession no. 
KM881710) isolated from the 2014 outbreak in the United States 
was used for this analysis. Like other picornaviruses, the viral cul-
ture of EV-D68 in vitro yields two major types of particle: procap-
sid and mature virion (Supplementary Fig. 1a,b). On addition of 
the functional receptor ICAM-5, viral genomic RNA in mature 
virions was exposed and vulnerable to degradation at a signifi-
cantly lower temperature (about 30 °C) than in untreated mature 
virions (about 55 °C) based on a particle stability thermal release 
assay (Supplementary Fig. 1e). These data suggest that ICAM-5 
triggered transformation of EV-D68 mature virions to A-particles 
(A-particle_i5) in vitro (Supplementary Fig. 1c–e). We then deter-
mined the cryoEM structures of these three capsid forms at near-
atomic resolutions (3.8, 3.4 and 4.0 Å for the procapsid, mature virion 
and A-particle_i5, respectively; Fig. 1a–c and Supplementary Figs. 2 
and 3). Of note, approximately 4% of particles were excluded dur-
ing image processing selection on mature virions (Supplementary 
Fig. 2). Three-dimensional (3D) reconstruction of the excluded 
particles yielded a 4.4-Å-resolution map of A-particles essentially 
identical to ICAM-5-induced A-particles (correlation coefficient 
value of 0.99; Supplementary Fig. 4). Therefore, this minor class 
of particles derived from the supernatant of virus-infected cells is 
now referred to as A-particles triggered by an unknown stimulus 
(A-particle_us). The density map derived from the major class of 
particles demonstrated that EV-D68 mature virions feature a com-
pactly packed capsid with a maximum diameter of ~320 Å along 
its five-fold axis (Fig. 1a). Compared to the mature virion, the pro-
capsid and A-particle resemble the capsid structure (correlation 
coefficient 0.94), but share expanded diameters of ~330 Å along 
five-fold axes and open two-fold channels (Fig. 1a–c). The density 
attributable to encapsidated genome is present in both mature viri-
ons and A-particles, but absent in procapsids (Fig. 1d–f). However, 
the genome in the A-particle seems more organized and interacts 
more directly with the inner surface of the capsid (Fig. 1f), which 
implies that it is poised for release into the host cell. To our surprise, 
no interpretable density of cellular receptor ICAM-5 was observed 
in 2D/3D classifications or final 3D reconstruction of ICAM-5-
triggered A-particles, indicating that the binding of ICAM-5 with 
the capsid might be transient with low affinity, or the receptor-bind-
ing site may be lost after the transformation.
The density maps of all three types of particle show clear 
delineation of protein backbones and resolve side chains of most 
amino-acid residues, which allowed us to build their atomic 
models (Supplementary Table 1). Overall, our atomic model of 
the mature virion (clinical strain) is similar to that of the crystal 
structure of the EV-D68 mature virion (Fermon strain)9, with a 
root mean squared deviation (r.m.s.d.) of 1.07 Å for all Cα atoms 
in the overlay of each protomer (Supplementary Figs. 5 and 6 
and Supplementary Table 2). By contrast, structural compari-
son between protomers of the mature virion and the A-particle 
revealed conformational changes in the mature virion triggered 
by ICAM-5. Like some other picornaviruses15,16,22,23, the particle 
diameter expands ~3% and each protomer rotates anticlockwise 
by 3.5° with the pivot point located at the corner of VP3 close to 
the icosahedral three-fold axis (Fig. 1g, Supplementary Fig. 7a,b 
and Supplementary Video 1). The ICAM-5-triggered A-particle 
also shares some common features with the classical A-particles 
of other picornaviruses, such as collapsed pocket-factor-binding 
regions, externalized VP1 amino termini and lost VP4s, and open 
two-fold-axis channels (Fig. 1g and Supplementary Fig. 7c,d). 
Apart from these, the VP3 GH loop also undergoes a major con-
formational shift and forms a β -hairpin structure (Fig. 1g). Despite 
the different protein components, the capsid shells of the procap-
sid (comprised of VP0, VP1 and VP3) and the A-particle (consti-
tuted by VP1, VP2 and VP3) share a similar structure based on 
an r.m.s.d. of 0.73 Å for all Cα atoms between corresponding pro-
tomers. Superposition of the two models illustrates recognizable 
differences including a ~4 Å shift of VP1 HI loops and disordered 
versus identifiable density of VP3 GH loops in the procapsid and 
the A-particle, respectively (Fig. 1h). Since VP1 loops in some 
picornaviruses function as immunogenic targets for neutralizing 
antibodies13,17,24, we postulate that the distinct conformations of 
VP1 HI loops in EV-D68 A-particles and procapsids have ren-
dered antigenicity differences.
Anti-EV-D68 neutralizing antibodies 15C5 and 11G1 confer pro-
tective efficacies in vivo. To better explore the antibody-mediated 
neutralization of EV-D68 and antigenic profiles at different stages 
in its life cycle, we generated monoclonal antibodies in mice immu-
nized with supernatant from virus cultures. Two representative 
neutralizing antibodies, named 15C5 and 11G1, were selected for 
further functional and structural analysis. In binding assays, 15C5 
shows high binding efficiency for both mature virions and procap-
sids in a concentration-dependent manner, whereas the binding 
of 11G1 to either type of particle is relatively weak (Fig. 2a,b). In 
virion-based neutralization assays, 15C5 showed 30-fold higher 
neutralizing potency than 11G1, manifested by half-maximum 
inhibitory concentration (IC50) values of 1.5 versus 39.7 μ g ml−1  
(Fig. 2c). These findings suggested that the two neutralizing anti-
bodies neutralize via distinct mechanisms. Furthermore, in the 
RNA-binding fluorescent assay, the accessibility of the dyes to 
mature virions with or without the presence of 11G1 remains at 
about the same level, suggesting minimum genome exposure 
except at non-physiological temperatures from 50 °C to 60 °C. 
In contrast, the binding of 15C5 to the EV-D68 mature virion sig-
nificantly increases the accessibility of the dyes to the genomic RNA 
and prominent fluorescence was detected at 37 °C (Fig. 2d). Taken 
together, these data suggest that 15C5 binding to mature virions 
induces conformational changes in the capsid, and 11G1 does not 
neutralize virus by binding to mature virions.
The protective efficacy against mortality for 15C5 or 11G1 used 
to treat infection was measured in vivo in 1-day-old mice that 
were challenged with the lethal dose of a clinical EV-D68 strain. 
To evaluate the therapeutic efficacy, we administered either anti-
body to mice at 24 h post-infection. The survival rate of the mice in 
the 15C5-treated (60 μ g g−1) group was 100%, and 11G1 treatment 
resulted in reduced illness severity and delayed mortality compared 
to the control group (Fig. 2e). For prophylaxis, mice were adminis-
tered the same dosage of either 15C5 or 11G1 at 12 h before virus 
challenge. Mice pre-treated with 15C5 showed a 100% survival rate, 
and those with 11G1 had delayed onset of mortality when com-
pared to the control group (Fig. 2f).
To further explore the neutralization mechanisms of 15C5 and 
11G1, a cell-based PCR with reverse transcription (RT–PCR) assay17 
was used to quantify the ability of these antibodies to block virus 
particles from attaching to host cells. When pre-mixed with EV-D68 
virus, either 15C5 or 11G1 can reduce the number of particles bound 
to host cells. 15C5 demonstrated higher potency than 11G1 for inhib-
iting viral attachment and the effect was concentration-dependent 
(Fig. 2g,h). Since 11G1 cannot bind to mature virions effectively, 
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we performed a post-attachment neutralization assay to investigate 
whether 11G1 can neutralize virus after attachment of EV-D68 to 
the cell. As shown in Fig. 2i, 11G1 could neutralize viruses in a post-
attachment manner with an IC50 value of 39.0 μ g ml−1 that is com-
parable to the neutralization potency (IC50 = 39.7 μ g ml−1) under 
regular conditions (Fig. 2c).
CryoEM structures of 15C5 or 11G1 complexes with EV-D68 and 
15C5-triggered structural transformation. The binding profiles 
of 15C5 and 11G1 to three forms of EV-D68 capsid were further 
evaluated with cryoEM and 2D classification using Relion soft-
ware25. The data indicated that 15C5 efficiently binds to all three 
types of particle, and that 11G1 binds only to A-particles, exhibiting 
a b c
d e f
g h
5
3 2
5
3
3
ProcapsidMature virion A-particle
90
120
150
180
VP1 N termini
VP1 HI loop
VP3 GH loop VP3 GH loop
ProcapsidMature virion A-particle
3.5°
Radius (Å)
Fig. 1 | The cryoeM structures of eV-D68 particles. a–c, Iso-contoured views (along the icosahedral two-fold axis) of cryoEM maps (radially coloured) of 
the mature virion (a), procapsid (b) and A-particle (c). One icosahedral asymmetric unit is marked by a white triangle in a. The procapsid and A-particle 
show capsids with open two-fold channels, which are closed in the mature virion. d–f, Central sections of the corresponding maps displayed in the upper 
row. The densities of encapsidated genomic RNA are present in both the mature virion (d) and A-particle (f), but absent in the procapsid (e).  
g,h, Superpositions of protomers of A-particle protomer (VP1: blue; VP2: green; VP3: red) with that of mature virion (grey) (g) or procapsid (grey) (h). The 
orientation of the protomers is marked by black polygons indicating icosahedral five-, three- and two-fold axes, respectively. The colour scheme for the 
capsid proteins will be kept the same in all figures unless noted otherwise. The regions of the most significant differences between models are highlighted 
with magnified views in the dashed boxes: VP1 N termini (upper box) and VP3 GH loops (lower box) between the A-particle and the mature virion (g); VP1 
HI loops (upper box) and VP3 GH loops (lower box) between the A-particle and the procapsid (h).
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little or no binding to mature virions or procapsids (Supplementary 
Fig. 8). In addition, the density of 11G1 binding to A-particles is 
less than that of 15C5, suggesting that 11G1 binding is not satu-
rating. 3D reconstructions of EV-D68 mature virion in complex 
with 15C5 (EV-D68-M:15C5) and A-particles_us in complex with 
11G1 (EV-D68-A:11G1) were determined at resolutions of 3.6 Å 
and 7.2 Å, respectively (Fig. 3a,b and Supplementary Fig. 9a–f). 
The density maps show that 15C5 and 11G1 target the virus capsid 
around its three-fold and five-fold vertices, respectively, and thus up 
to 60 copies of 15C5 or 11G1 Fabs can bind to each virus particle 
(Fig. 3a,b). Mimicking a property of ICAM-5, the binding of 15C5 
triggers the opening of two-fold channels in mature virions and 
reorganization of the genome (Supplementary Fig. 10).
We next built an atomic model of the EV-D68-M:15C5 complex, 
which includes three major capsid proteins (VP1, VP2 and VP3) and 
the variable domain of 15C5 Fab, but excludes the constant domain 
that has a disordered density in the cryoEM map (Supplementary 
Fig. 11a). Each Fab has a footprint that extends across two adjacent 
protomers, and its binding buries a total surface area of ~915 Å2 on 
the capsid (Fig. 3c). The heavy chain of Fab 15C5 binds across the 
VP2 BC loop and the VP3 BC loop from two adjacent protomers, 
accounting for ~76% of the buried area (Fig. 3d), and the light chain 
interacts with the AB, BC and HI loops of the same VP3 that binds 
the heavy chain (Fig. 3e). The Fab–capsid interaction establishes 
an elaborate hydrogen-bonding network including eight bonds 
formed between complementarity-determining regions H1, H3, L2 
and VP3 AB, BC, HI loops and VP2 BC, HI loops (Fig. 3d,e and 
Supplementary Table 3), and several van der Waals interactions are 
observed between the 15C5 Fab and the capsid (Supplementary 
Table 3). In addition, escape mutants were generated by propagating 
the viruses in the presence of 15C5. All 15C5-resistant mutants had 
an amino-acid change at position 74 (L74S), which is located at the 
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Fig. 2 | Characterization of the neutralizing antibodies 15C5 and 11G1. a,b, Binding efficiencies of the neutralizing antibodies 15C5 and 11G1 to EV-D68 
mature virion (a) or procapsid (b) evaluated with binding ELISA. The values are expressed as mean ±  s.d. The experiments were independently repeated in 
triplicate. c, Neutralization efficiencies of the neutralizing antibodies 15C5 and 11G1 against EV-D68 virus plotted as a function of their concentrations  
(IC50 titres are noted). d, Particle stability thermal release assay of EV-D68 mature virions and their complexes with either 15C5 or 11G1. The fluorescence 
value indicates the level of genome exposure relative to temperature. The fluorescence traces are shown for EV-D68 mature virions (green line) as well 
as their complexes with 15C5 (blue line) or 11G1 (red line). The experiments were independently repeated in triplicate. e,f, Antibody-mediated protection 
against EV-D68 infections. Groups of 1-day-old BALB/c mice (10 mice per group) were treated with either 15C5 or 11G1 24 h after (e) or 12 h before  
(f) infection with EV-D68 (106 TCID50 per mouse, i.p.). The mortality of each group was monitored and recorded daily after infection. g,h, The amount 
of cell-bound EV-D68 viruses detected by quantitative real-time RT–PCR in the presence of the neutralizing antibody 15C5 (g) or 11G1 (h) added before 
the viruses. The values are expressed as mean ±  s.d. The experiments were independently repeated in triplicate. i, Post-attachment neutralization assay 
of theneutralizing antibody 11G1 shows comparable neutralization capacity to that of regular conditions. The values are expressed as mean ±  s.d. The 
experiments were repeated in triplicate. The IC50 was calculated by nonlinear regression fitting curves using GraphPad Prism version 7.0.
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VP3 BC loop and is a critical contact residue in the virus–antibody 
interaction (Supplementary Table 3).
The capsid in the immune complex EV-D68-M:15C5 exhibits a 
notably different structure from that of the EV-D68 mature virion, 
but similar to ICAM-5-induced A-particles (the r.m.s.d. between 
protomers from two respective models is 0.48 Å; Supplementary 
Fig. 11b). Moreover, binding of three 15C5 Fabs at each three-fold 
axis occurs with variable regions packed tightly together (Fig. 4a). 
Thus, we used the 3 three-fold-related asymmetric units of EV-D68-
M:15C5 for individually superimposing onto the model of the 
mature virion (Fig. 4b,c). The overlay showed subtle conformation 
changes in the VP2 HI loop (with the Cα atom shifted by 3.2 Å) and 
the VP3 BC loop (with the Cα atom shifted by 3.8 Å), and we believe 
the changes are necessary to accommodate the binding of adjacent 
15C5 Fabs since both loops were directly involved in the interaction 
(Fig. 4b). The comparison also revealed that the three Fabs became 
closer to each other in the superimposed model than in the original 
model of the 15C5 immune complex (Fig. 4c). Arg 24L and His 62H 
are the two nearest residues (distance of 2.9 Å) between neighbour-
ing heavy and light chains in adjacent Fabs, and are distant from the 
virus–antibody binding interface in the original immune-complex 
model. In the superimposed models, these two residues exhibit a 
steric clash (Fig. 4d). To accommodate the physical proximity of the 
adjacent Fabs, we hypothesize that when 15C5 binds mature viri-
ons, the VP2 HI loop and the VP3 BC loop are pushed apart to 
trigger the conformational change from mature virion to A-particle 
via a cascade of molecular rearrangements and allosteric effects. 
This results in an anticlockwise movement of ~2.7 Å of each Fab 
along the three-fold axis (Fig. 4c,d).
CryoEM structure of EV-D68 bound with both neutralizing 
antibodies 15C5 and 11G1. We next sought to build the double-
antibody complex EV-D68-M:15C5:11G1 by adding 11G1 to the 
EV-D68-M:15C5 complex. A triple immune complex was success-
fully generated and its cryoEM density map was reconstructed at 
a final resolution of 3.5 Å (Supplementary Fig. 9g–i). A total of 60 
copies of 15C5 and 60 copies of 11G1 concurrently bound to the 
transformed A-particle at icosahedral three-fold and five-fold verti-
ces, respectively (Fig. 5a,b). The densities attributable to 11G1 were 
dramatically improved in this complex when compared with those 
in the EV-D68-A:11G1 complex (Supplementary Fig. 8), which 
indicates that 11G1 may favour A-particles converted from mature 
virions triggered by 15C5 rather than ICAM-5.
In the triple immune complex, the interaction between 15C5 
and the capsid is essentially identical to that in the EV-D68-M:15C5 
complex (Supplementary Figs. 11c,d and 12). Nevertheless, the 
atomic model allowed us to further refine the epitope for 11G1. 11G1 
interacts with BC, DE, EF and HI loops and two β -strands of VP1, 
which buries a total surface area of ~970 Å2 on the capsid (Fig. 5c 
and Supplementary Fig. 12). Notably, the VP1 BC loop is anchored 
and well resolved by the binding of 11G1 (Fig. 5d), whereas the loop 
is disordered in the other structures of all three forms of individual 
particles as well as the EV-D68-M:15C5 immune complex. In addi-
tion, the binding of 11G1 induces minor conformational changes 
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of the VP1 BC and HI loops that both rotate about 3.5° away from 
the Fab relative to the VP1 framework region when compared with 
those in the EV-D68-M:15C5 complex (Fig. 5d). The interaction 
interface between 11G1 and the capsid involves 3 (L1, L3 and H3) 
of the 6 complementarity-determining regions, which forms 14 
hydrogen bonds and several van der Waals contacts with the VP1s 
(Fig. 5e,f and Supplementary Table 4). Among these hydrogen 
bonds, two (Tyr 103H–Glu 75 and Tyr 103H–Thr 234) are formed 
by each 11G1 Fab binding VP1 across adjacent protomers. To fur-
ther confirm the epitope recognized by 11G1, virus escape mutants 
were generated under the immune pressure of 11G1; the resul-
tant 11G1-resistant viruses harboured a mutation at position 229 
(Q229K) or position 234 (T234A) of VP1, both of which are located 
in the virus–antibody binding interface (Supplementary Table 4).
Neutralizing antibodies 15C5 and 11G1 inhibit viral infection 
via distinct mechanisms. Picornaviruses enter cells via receptor-
mediated endocytosis where A-particles may form within the 
endosome of the infected cell26,27. However, on the basis of previous 
work17,28–31 and the structures of three capsid forms in this study, 
the mature virion interacts with cellular receptors anchored on 
the surface of host cells, which may lead to transformation into 
the A-particle conformation before endocytosis, and would be 
considered as an alternative route for virus entry (Supplementary 
Fig. 13). The binding of 15C5 can also induce the conformational 
change similar to that induced by ICAM-5 binding, indicating 
that the 15C5-binding sites (VP2 HI loop and VP3 BC loop) may 
serve as sensors to trigger capsid transformation. Unlike ICAM-
5, which binds to virus particles in a transient manner, 15C5 
engages mature virions with high efficiency (Fig. 3a) and efficiently 
blocks the subsequent A-particle from attaching to the cell surface 
(Fig. 2g) thereby neutralizing viral infection before attachment 
(Fig. 2c,f). In contrast, 11G1 exclusively recognizes the A-particle 
rather than the mature virion, which suggests that 11G1 neutralizes 
with assistance from other factors, such as ICAM-5 or 15C5-like 
antibodies. The post-attachment inhibition effect of 11G1 (Fig. 2i) 
suggests that 11G1 neutralizes viruses after attachment, but before 
endocytosis. The neutralizing antibody 11G1 binds two adjacent 
protomers from neighbouring VP1s (Fig. 5c) and may potentially 
achieve neutralization by interfering with genome release from the 
A-particles into host cells (Supplementary Fig. 13).
Taken together, 15C5 binds the three-fold axis of the viral capsid, 
triggers the transformation of mature virions to A-particles, stays 
bound, and blocks binding to host cells. The neutralizing antibody 
11G1 binds the five-fold axis, but only on the A-particle. Therefore, the 
two antibodies examined in this study neutralize EV-D68 in spatially, 
a b
c d
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HI loop
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BC loopVH
VL
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H62
15C5-VH
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15C5-VL
Fig. 4 | Superposition of mature virion with or without the binding of 15C5 shows details of 15C5-induced conformational changes. a, Outside view of 
the density attributable to the 3 three-fold-related asymmetric units segmented out of the cryoEM map of EV-D68-M:15C5. The capsid density (grey) 
is fitted with atomic models of three major capsid proteins and, for clarity, only the variable domains of three Fabs are shown. b, The 3 three-fold-related 
asymmetric units of EV-D68-M:15C5 (coloured wire diagram) are individually superimposed onto the models of the mature virion (grey). The scope of 
the epitope region is marked by the dashed ellipse. The significant conformational changes occurring at the VP2 HI loop and the VP3 BC loop after the 
binding of Fabs are highlighted. c,d, Atomic models of the three Fabs in a (coloured wire diagram) together with three superimposed Fabs (grey). The 
superimposed Fabs, which show a 2.7 Å movement and became closer when compared to the original model of the 15C5 immune complex, represent the 
theoretical binding of Fabs to the mature virion at the same epitope prior to conformational changes of the capsid. The close-up view (d) shows that the 
two nearest residues (distance of 2.9 Å) between neighbouring heavy and light chains are His 62H and Arg 24L derived from two adjacent Fabs. These two 
amino acids exhibit a steric clash in the superimposed models (grey).
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temporally and functionally distinct manners, and potentially block 
virus infection at different stages of the EV-D68 life cycle.
Discussion
Picornaviruses initiate infection by mature virions binding the cellu-
lar receptor, triggering endocytosis and conformational transforma-
tion to A-particles, leading to the release of viral genome into host cell 
cytosol23,32,33. High-resolution structural analysis of mature virions, 
A-particles and their complexes with cellular receptors is critical for 
understanding the molecular and structural basis of this dynamic 
uncoating process15,34. Structural investigation of EV71 particles 
has suggested a sensor–adaptor (VP1 GH loop) triggering mech-
anism for virus uncoating13. In our study, near-atomic-resolution 
structures of the EV-D68 procapsid, mature virion and A-particles 
(unknown stimulus-induced, ICAM-5-induced or 15C5-induced) 
and their immune complexes offer a framework for understanding 
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Fig. 5 | The cryoeM structure of eV-D68 in complex with 15C5 and 11G1. a, Iso-contoured views of the cryoEM map (radially coloured) of the immune 
complex EV-D68-M:15C5:11G1. The EV-D68 capsid is bound with 60 copies of Fab 15C5 at three-fold axes and 60 copies of Fab 11G1 at five-fold axes, 
respectively. b, A quarter of the central section of the cryoEM map in a; the radii are marked by the arcs. c, Surface representation shows the interaction 
interface of Fab 11G1. Each Fab 11G1 (heavy chain: magenta; light chain: orange) binds across two neighbouring VP1s (light blue and blue) of the capsid. 
Footprints of the VH and VL of the Fab on the capsid are coloured with magenta and orange. d, A close-up view (wire diagram) of the interaction interface 
between 11G1 and the capsid shows the conformational changes (indicated with black arrows) of the VP1 BC loop and HI loop before (grey) and after 
(coloured) binding with 11G1. e,f, Close-up views of the interaction interfaces between the capsid and the light (e) or heavy chain (f) of Fab 11G1. Potential 
hydrogen bonds are marked by yellow dashed lines.
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the mechanics of EV-D68 particle transformation and uncoating, 
and mechanisms of virus neutralization (Supplementary Fig. 13). 
We demonstrated that the EV-D68 mature virion can initiate cell 
entry by binding to a cellular receptor ICAM-5 that triggers the 
formation of a necessary intermediate (A-particle). This transfor-
mation results in a reorganization of the RNA genome, suggesting 
that this step may be critical for release of genome into the host 
cell and initiation of infection. We also demonstrated two distinct 
antibody-mediated mechanisms of viral neutralization. Binding 
of 15C5 at the three-fold axes induces a conformational change 
of EV-D68 mature virions to A-particles that is a prerequisite for 
subsequent genome release16,35,36. In addition to triggering the con-
formational change to A-particles, 15C5 also inhibits attachment 
of A-particles to cell surface receptors and thereby neutralizes viral 
infection. Structural analysis on immune complexes showed that 
15C5 recognizes a quaternary epitope that bridges across VP3 and 
the VP2 from two adjacent protomers, which may lock the capsid 
at an intermediate stage and prevent further conformational change 
and the uncoating process. Notably, this neutralization mechanism 
is different from some other reported antibodies against EV71 or 
HRV, which have been shown to induce premature viral uncoat-
ing and genome release21,22. 11G1 appears to neutralize enterovirus 
by a unique post-attachment mechanism. After cell engagement by 
mature virions triggers transformation to the A-particle, 11G1 is 
able to bind at a step before endocytosis and neutralize virus infec-
tion. The specificity and structural complementarity of these two 
antibodies and distinct timing and neutralizing activity suggest that 
the two antigenic sites recognized by 15C5 and 11G1 may serve as 
excellent targets for the design of vaccines and antiviral therapeutics 
against EV-D68.
From an immunological viewpoint, an epitope (such as of 15C5) 
located on the mature virion can escape neutralization in vivo by 
genetic variation under the pressure of the neutralizing antibody 
response. However, an epitope (such as of 11G1) revealed transiently 
during the capsid transition to an A-particle conformation may be 
less susceptible to escape mutation. We propose that A-particles, 
bearing both the 15C5-like epitope and the unique 11G1-like epit-
ope, may be the preferred antigenic form for the design of vaccine 
candidates against the canonical native virion. Our study revealed 
a potential approach for generating stable EV-D68 A-particles by 
exposing isolated virions to ICAM-5 or 15C5. The atomic-level 
definition of immune complexes provides a basis for confirming 
antigenic integrity of candidate vaccines. Therefore, the antibodies 
15C5 and 11G1 provide important tools for structure-based vaccine 
design and could potentially be developed as therapeutic interven-
tions for EV-D68 infections.
Methods
Cells and viruses. Human RD (Rhabdomyosarcoma) cells were obtained from 
the American Type Culture Collection (ATCC, CCL-136) and maintained in 
Minimal Essential Medium (Gibco) supplemented with 10% fetal bovine serum 
(Gibco). The cells were routinely tested and confirmed negative for contamination 
with mycoplasma. The EV-D68 strain STL-2014–12 (GenBank accession no. 
KM881710) infectious clone was constructed in our laboratory and propagated in 
RD cells. Virus were stored in aliquots at − 80 °C.
Virus production and purification. EV-D68 was propagated in RD cells at a 
multiplicity of infection of 0.2 at 33 °C. Virus was collected 3 days after infection, 
and then centrifuged at 7,000g for 30 min to remove cell debris and precipitated 
by using 7% (w/v) polyethylene glycol 8000 (PEG 8000) and 0.2 M NaCl in 0.1 M 
phosphate buffer (PB, pH 7.4) at 4 °C for 12 h. After centrifugation, virus was 
resuspended and then sedimented through a linear 15–45% (w/v) sucrose density 
gradient at 140,000g for 3 h at 4 °C using a Beckman SW41 Ti rotor. Two fractions 
were collected and independently dialysed against PB (pH 7.4) and concentrated 
by an Ultra-4 centrifugal concentrator. The quantity and quality of EV-D68 virions 
were examined by negative-staining electron microscopy.
Neutralization assay. RD cells were prepared in Minimal Essential Medium 
supplemented with 2% fetal bovine serum and seeded at 1 × 104 cells per well 
into 96-well plates. For neutralization assay, monocolonal antibodies were 
serially diluted by twofold dilutions (the initial concentration of 1 mg ml−1) 
and incubated with an equal volume of EV-D68 (100 TCID50) at 33 °C for 1 h; 
then the virus/monocolonal antibody mixture was added to 96-well plates 
pre-seeded with RD cells. For post-attachment neutralization assay, EV-D68 
(100 TCID50) was added to 96-well plates pre-seeded with RD cells and incubated 
at 4 °C for 1 h. Then, serially twofold-diluted 11G1 (the initial concentration of 
1 mg ml−1) was added to the virus/cell plate. The 96-well plates were incubated 
at 33 °C for 3–5 days. The cytopathic effects (CPEs) were observed under a 
microscope, and the neutralization titres were read as the highest dilution of cells 
protected from 50% CPE, taken as the average of the triplicates. The relative cell 
viability (%) was measured by a MTT assay. The percentage of neutralization 
of the antibody was calculated with the following formula: percentage of 
neutralization = (ODtest – ODvirus control)/(ODcell control – ODvirus control) × 100%. The  
EV-D68 titre (TCID50) was calculated using the Reed–Muench method.
Binding enzyme-linked immunosorbent assay. The purified EV-D68 mature 
virions and procapsids were adsorbed at 50 ng per well in PB (pH 7.4) to enzyme-
linked immunosorbent assay (ELISA) plates (96-well) at 4 °C overnight. Each well 
was blocked with BSA–PBS (1% bovine serum albumin in PBS) at 37 °C for 2 h, 
after washing with PBST (0.05% Tween-20 in PBS). Antibodies, ICAM-5 (ICAM-
5-Fc; R&D, 1950-M5–050) or IgG1-Fc (R&D, 110-HG-100) were added at various 
concentrations and incubated at 37 °C for 1 h. Each well was then incubated with 
GAM–HRP or GAH–HRP secondary antibody at 1:5,000 dilutions at 37 °C for  
30 min. After colour development using TMB chromogen substrate and the 
reaction stopped with 2 M H2SO4, absorbance was measured at A450/620 nm.
Particle stability thermal release assay. Thermofluor experiments37 were 
performed with an MX2005p RT–PCR instrument (Agilent). The environment-
sensitive fluorescent dye SYTO9 (Invitrogen, S34854) was used to detect the 
presence of RNA. Each 50 μ l reaction was set up in a thin-walled PCR plate, 
containing 1.0 μ g of EV-D68 mature virion and 5 μ M SYTO9 in PBS. The 
temperature was ramped from 25 to 99 °C with the fluorescence level recorded 
in triplicate at 0.5 °C intervals. In addition, a similar assay was also performed on 
virus–monoclonal antibody or virus–ICAM-5 complexes with 1.0 μ g of EV-D68 
mature virion pre-incubated with either 2.5 μ g of antibody or 3 μ g of ICAM-5 
protein. The RNA release (Tr) and melting temperature (Tm) were taken as the 
minimums of the negative first derivative of the RNA exposure and protein 
denaturation curves, respectively.
In vivo protection test. BALB/c mice were obtained from the Slac Laboratory 
Animal Co. Animal experiments were approved by Xiamen University Laboratory 
Animal Center (XMULAC). All procedures were conducted in accordance with 
animal ethics guidelines and approved protocols. All mice used in the study were 
randomly assigned to the different groups. Experiments were not performed in a 
blinded fashion. Groups of neonatal BALB/c mice (n = 10, gender-random) were 
inoculated intraperitoneally (i.p.) with 50 μ l of neutralizing antibodies (60 μ g g−1 
body weight) or PBS buffer at 24 h after or 12 h before infection i.p. with 50 μ l of 
EV-D68 (106 TCID50 per mouse). The mice in the control groups were treated with 
50 μ l of PBS. Daily monitoring of body weight and clinical disease continued in 
mice 20 days post infection.
Pre-attachment inhibition assay. The virus pre-attachment assays were conducted 
as previously described17. In brief, EV-D68 virus was mixed with serially diluted 
monoclonal antibody 15C5 or 11G1 at 4 °C for 1 h before the virus attached to pre-
seeded cells in 96-well plates. After three washes with cold PBS to remove unbound 
viruses, total cellular RNA was extracted using the QIAamp Mini viral RNA 
Extraction Kit (Qiagen). The amount of cell-bound virus RNA was determined by 
quantitative real-time RT–PCR. The analysis of relative levels of EV-D68 RNA in 
different samples was performed by the comparative 2-Δ Δ CT method38.
Preparation of antibodies and antibody fragments. To obtain the anti-EV-D68 
monocolonal antibodies 15C5 and 11G1, BALB/c mice were immunized with 
the supernatant of virus culture emulsified in complete Freund’s adjuvant and 
boosted twice at two-week intervals with supernatant in incomplete Freund’s 
adjuvant. Then spleen cells from immunized mice were fused with myeloma 
cells (Sp2/0Ag-14) and hybridoma supernatant was screened, using ELISA and 
neutralization assay against EV-D68. Antibodies were purified from mouse ascitic 
fluid by protein A affinity chromatography. The variable region sequences of 
antibodies were determined by cloning and sequencing of their complementary 
DNA. To obtain antibody Fab fragments, monoclonal antibody 15C5 or 11G1 was 
digested with 1 ‰ (w/w) papain in 0.02 M PB (pH 7.0), containing 0.03 M  
l-Cys and 0.05 M EDTA at 37 °C for 10–12 h. After adding 30 mM iodoacetamide, 
the resulting antibody fragment (Fab) was purified via DEAE column (TOSOH) 
chromatography.
Generation and sequencing of the escape mutant viruses. 15C5 or 11G1  
(200 μ g ml−1) was incubated with 1 × 107 TCID50 of EV-D68 for 1 h at room 
temperature, followed by 2 h at 37 °C. The mixtures were added to RD cells and 
NATuRe MiCRoBioLoGY | www.nature.com/naturemicrobiology
ArticlesNATurE MICrObIOlOGy
incubated at 37 °C until CPE developed. After three freeze–thaw cycles, the 
cultures were clarified by centrifugation. The second and third round of infection 
in the presence of 15C5 or 11G1 was performed with the antibody concentration 
of 800 μ g ml−1. The obtained 15C5- or 11G1-resistant viruses were purified from 
plaques and then cloned into RD cells. The P1 region of the mutated viral genome 
was amplified by RT–PCR and subsequently verified by DNA sequencing.
CryoEM sample preparation and data acquisition. EV-D68 A-particle was 
prepared by the mixture of mature virion with ICAM-5 at a molar ratio of five 
ICAM-5 to every viral particle. EV-D68 immune complexes were prepared by the 
mixture of mature virion with Fab 15C5 or 11G1 or both at a molar ratio of 72 Fab 
to every viral particle. All of the mixtures were incubated for 30 min at 37 °C. 
Aliquots (3 μ l) of purified procapsid, mature virion, ICAM-5-induced A-particle or 
immune complexes were deposited onto glow-discharged holey carbon Quantifoil 
Cu grids (R2/2, 200 mesh, Quantifoil Micro Tools) inside an FEI Mark IV Vitrobot 
at a humidity level of 100%. After 6 s blotting, the grids were plunge-frozen into 
liquid ethane cooled by liquid nitrogen. Specimens were examined under low-dose 
conditions at 300 kV with a FEI Tecnai F30 transmission electron microscope. 
All images were recorded on a Falcon II direct electron detector in the 17-frame 
video mode at a nominal magnification of 93,000, corresponding to a pixel size of 
1.128 Å, and with the defocus ranging from 1.5 to 3.0 μ m. The total electron dose 
was set to 25 e− Å−2 and the exposure time was 1 s. FEI software EPU was used 
for all data collection; micrographs with drift and astigmatism were discarded. 
In total, 774 (mature virion), 677 (procapsid), 1,792 (A-particle), 2,414 (EV-D68-
M:15C5), 189 (EV-D68-A:11G1) and 1,785 (EV-D68-M:15C5:11G1) micrographs 
were selected with a defocus range of 0.7–2.8, 0.9–3.6, 0.8–3.8, 0.7–4.1, 1.7–4.2 and 
1.0–4.5 μ m respectively, for further image processing.
Image processing. Video frame alignment and contrast transfer function 
estimation of each aligned micrograph were carried out with the programs 
Motioncor239 and Gctf40. A total of 45,822 (mature virion), 14,265 (procapsid), 
25,045 (A-particle), 105,346 (EV-D68-M:15C5), 414 (EV-D68-A:11G1) and 
143,304 (EV-D68-M:15C5:11G1) particles were auto-picked by the Autopick 
session of software Relion 2.025. Initial 3D models of each of the six types of particle 
were generated with a random model method using AUTO3DEM41. Two rounds 
of reference-free 2D classifications, two rounds of unsupervised 3D classifications 
and final 3D reconstruction were all performed with Relion 2.0. A total of 11,938 
(mature virion), 13,849 (procapsid), 9,625 (A-particle), 58,540 (EV-D68-M:15C5), 
375 (EV-D68-A:11G1) and 102,512 (EV-D68-M:15C5:11G1) particles were 
included in final 3D reconstructions, respectively. The resolutions of the final maps 
were estimated on the basis of the gold-standard FSC curve with a cutoff at 0.14342. 
Local resolution variations were estimated using ResMap43.
Model building and refinement. Ab initio model building of all three particles 
and the immune complexes EV-D68-M:15C5 and EV-D68-M:15C5:11G1 was 
carried out in Coot44. The X-ray model of EV-D68 (PDB code 4wm8) was used 
for modelling the EV-D68 mature virion. The atomic models of CVA6 (PDB code 
5xs4) and its immune complex (PDB code 5xs7) served as templates to build 
models of the procapsid, A-particle and immune complexes of EV-D68. Briefly, 
these templates were manually fitted into the segmented volume (including 
an asymmetric unit) of the final cryoEM maps of viral particles and immune 
complexes, respectively. Sequence assignment was guided by aromatic and other 
residues with bulky side chains. Atomic positions of residues were manually 
built and modified using Coot and further refined using the module phenix.
real_space_refine in PHENIX44,45. After five cycles of refinement, problematic 
regions, Ramachandran outliers and poor rotamers were corrected in Coot. 
Then the resulting models were fitted into the density of the other six subunits 
in an asymmetric unit, which were executed as a whole for real-space model 
optimization, ensuring that clashes from neighbouring asymmetric units were 
avoided and optimized. Model statistics including bond lengths, bond angles, 
all atom clashes, rotamer statistics, Ramachandran plot statistics and so on were 
closely inspected with Coot during the whole process. Finally, additional validation 
of the models was performed with Molprobity46. The sequence alignments were 
carried out using Clustal W and Clustal X version 2 on the EBI server and rendered 
using ESPript software47. Density-map-based visualization, segmentation and video 
generation were then performed with Chimera48. Fab densities in the difference 
maps were projected on a stereographic sphere using RIVEM49. The Fab–capsid 
interactions were analysed using the software CCP450 and the PISA server  
(www.ebi.ac.uk/pdbe/pisa) with the donor to acceptor distances ≤ 4 Å for 
hydrogen-bond and salt-bridge interactions and ≤ 3.5 Å for other contacts.
Accession codes. The sequence of the VP gene of EV-D68 (this study), EV-D68 
(Fermon strain), EV-71, CV-A16, CV-A6 and CV-B3 can be found as GenBank 
accession no. KM881710, AY426531.1, FJ600325, FJ198212, KR706309 and 
M88483, respectively.
Data availability
The atomic coordinates of the mature virion, procapsid, A-particle_i5, EV-D68-
M:15C5 and EV-D68-M:15C5:11G1 have been deposited in the Protein Data 
Bank (accession numbers 6AJ0, 6AJ3, 6AJ2, 6AJ7 and 6AJ9, respectively). The 
cryoEM maps of the mature virion, procapsid, A-particle_us, A-particle_i5, 
EV-D68-M:15C5, EV-D68-A:11G1 and EV-D68-M:15C5:11G1 have been 
deposited in the Electron Microscopy Data Bank (accession numbers EMDB-
9629, EMDB-9632, EMDB-9635, EMDB-9631, EMDB-9633, EMDB-9636 and 
EMDB-9634, respectively).
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